CSIMarket Company Name, Ticker, Suppliers, else..


Bright Minds Biosciences Inc   (DRUG)
Other Ticker:  
 


 

Bright Minds Biosciences Inc

DRUG's Financial Statements and Analysis



Bright Minds Biosciences Inc increased forth quarter of 2023 net loss per share of $-1.52 compare to net loss per share of $-0.93 recorded in the same quarter a year ago a decrease compare to $0.00 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -1.52 $  0 Mill
$-0.59     Unch.    



Bright Minds Biosciences Inc 's Revenue fell by 0 % in forth quarter of 2023 (Sep 30 2023) year on year, to $0 million and declined by sequentially.


Bright Minds Biosciences Inc is

More on DRUG's Income Statement



Bright Minds Biosciences Inc in the forth quarter of 2023 recorded net loss of $-5.647 million, an improvement compare to net loss of $-11.463 million in IV. Quarter a year ago.

Sequentially company realized a net loss, compared to net income of $0.000 million in the previous quarter.

More on DRUG's Growth

Bright Minds Biosciences Inc Inventories
DRUG's Cash flow In the forth quarter of 2023 company's net cash flow was $9 million


Bright Minds Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Bright Minds Biosciences Inc payed $ -1.45 cash per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $1.36 per share.
Tangible Book value fell to $ 1.36 per share from $ 1.36.

Company repurchased 0.00 million shares or 0.00 % in Sep 30 2023.


• More on DRUG's Dividends

 Market Capitalization (Millions) 142
 Shares Outstanding (Millions) 4
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Bright Minds Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Bright Minds Biosciences Inc had negative $ -1.45 cash flow per share, on a free-cash flow basis .

Book value fell by 0.00 % sequentially to $1.36 per share.
Tangible Book value fell to $ 1.36 per share from $ 1.36.

Company repurchased 0.00 million shares or 0.00 % in Sep 30 2023.


• More on DRUG's Balance Sheets

 Market Capitalization (Millions) 142
 Shares Outstanding (Millions) 4
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -6
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Bright Minds Biosciences Inc Earnings

Bright Minds Biosciences Inc Shines Brightly, Delighting Shareholders with Impressive Fiscal Results



The Major Pharmaceutical Preparations sector has recently witnessed significant developments in the financial performance of Bright Minds Biosciences Inc. Although the company is yet to generate any revenue, the analysis of its fourth-quarter 2023 earnings reveals a notable improvement compared to the previous year. With a substantial reduction in the operating deficit and efforts by the executives to improve efficiency, Bright Minds Biosciences Inc is positioning itself for a prosperous future.
Positive Financial Indicators
The reported operating deficit for the period from July to September 2023 stands at $-4.521761578 million, marking a considerable decrease from $-10.381185126 million i...